13 Nov, 2021 New Results for Zilebesiran Presented at AHA Scientific Sessions 2021
Positive interim findings from the ongoing Phase 1 study of zilebesiran (formerly known as ALN-AGT) in adults with hypertension were presented during the American Heart Association (AHA) Scientific Sessions 2021 (Nov. 13-15).
Huang, et al. “Durable Reductions in Circulating Angiotensinogen and Blood Pressure 6 Months after Single Doses of ALN-AGT, an RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, in Hypertensive Patients”
Huang, et al. “Safety and Tolerability of ALN-AGT, an RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, in Hypertensive Patients during Sodium Depletion or Irbesartan Coadministration”
Results demonstrated that a single dose of investigational zilebesiran led to sustained serum angiotensinogen (AGT) and blood pressure (BP) reductions through six months, supporting quarterly and potentially biannual dosing regimens. Additional findings from other parts of the Phase 1 study showed that zilebesiran was safe and well tolerated during salt restriction and when administered concomitantly with irbesartan, an oral renin-angiotensin-aldosterone system inhibitor (RAASi).
Across various cohorts in the Phase 1 study, zilebesiran was shown to be generally well tolerated, supporting continued development.